High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial

Cancer Discovery

Volumn 6, Issue 8, 2016, Pages 838-851

  Pearson, Alex ^a   Smyth, Elizabeth ^b   Babina, Irina S ^a   Herrera Abreu, Maria Teresa ^a   Tarazona, Noelia ^a   Peckitt, Clare ^b   Kilgour, Elaine ^c   Smith, Neil R ^c   Geh, Catherine ^c   Rooney, Claire ^c   Cutts, Ros ^a   Campbell, James ^a   Ning, Jian ^a   Fenwick, Kerry ^a   Swain, Amanda ^a   Brown, Gina ^d   Chua, Sue ^e   Thomas, Anne ^f   Johnston, Stephen R D ^b   Ajaz, Mazhar ^g   Sumpter, Katherine ^h   Gillbanks, Angela ^b   Watkins, David ^b   Chau, Ian ^b   Popat, Sanjay ⁱ   Cunningham, David ^b   Turner, Nicholas C ^a,b   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d The Royal Marsden ^*  (United Kingdom)

^e Nuclear Medicine and PET CT Department   (United Kingdom)

^f LEICESTER ROYAL INFIRMARY   (United Kingdom)

^g ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^h FREEMAN HOSPITAL   (United Kingdom)

ⁱ Lung Pathology Unit   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; AZD 4547; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RAS PROTEIN; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; FIBROBLAST GROWTH FACTOR RECEPTOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE B; PYRAZOLE DERIVATIVE; TACHYKININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA PURIFICATION; DROPLET DIGITAL POLYMERASE CHAIN REACTION; DRUG SENSITIVITY; ESOPHAGUS CANCER; FEMALE; GASTROESOPHAGEAL CANCER; GENE ACTIVATION; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION; GENE MAPPING; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MOLECULAR CLONING; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE ADDICTION; ONCOLOGICAL PARAMETERS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN SYNTHESIS; RNA PURIFICATION; STOMACH CANCER; TRANSLATIONAL RESEARCH; WESTERN BLOTTING; XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLONAL EVOLUTION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELL LINE; X-RAY COMPUTED TOMOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BREAST NEOPLASMS; CELL LINE, TUMOR; CLONAL EVOLUTION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MOLECULAR TARGETED THERAPY; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TACHYKININS; TOMOGRAPHY, X-RAY COMPUTED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84982958036     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-1246     Document Type: Article

References (24)

1. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116–29.
2. Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013;3:264–79.
3. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012;72:2045–56.
4. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997–4013.
5. Herrera-Abreu MT, Pearson A, Campbell J, Shnyder SD, Knowles MA, Ashworth A, et al. Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. Cancer Discov 2013;3:1058–71.
6. Razzaque MS. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009;5:611–9.
7. Cha JY, Maddileti S, Mitin N, Harden TK, Der CJ. Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform. J Biol Chem 2009;284:6227–40.
8. Ueda T, Sasaki H, Kuwahara Y, Nezu M, Shibuya T, Sakamoto H, et al. Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. Cancer Res 1999;59:6080–6.
9. Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, et al. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 2013;19:3276–84.
10. Wang J, Wen S, Symmans WF, Pusztai L, Coombes KR. The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform 2009;7:199–216.
11. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202–9.
12. Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J, Lax I. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci U S A 2001;98:6074–9.
13. Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, Diefenbacher ME, et al. Requirement for interaction of PI3-kinase p110alpha with RAS in lung tumor maintenance. Cancer Cell 2013;24: 617–30.
14. Ueki K, Algenstaedt P, Mauvais-Jarvis F, Kahn CR. Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit. Mol Cell Biol 2000;20:8035–46.
15. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–92.
16. Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial. J Clin Oncol 2009;27:2962–9.
17. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008;68:2340–8.
18. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFRdependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011;104:75–82.
19. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.
20. Garcia-Murillas I, Lambros M, Turner NC. Determination of HER2 amplification status on tumour DNA by digital PCR. PLoS One 2013;8:e83409.
21. Chou TC. Drug combination studies and their synergy quantification using the Chou–Talalay method. Cancer Res 2010;70:440–6.
22. Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 2009;25:1754–60.
23. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297–303.
24. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31:213–9.